WFRF:(Viljanen T)
Sökning: WFRF:(Viljanen T) > Differential effect...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 03253naa a2200373 4500 | |
| 001 | oai:prod.swepub.kib.ki.se:1929045 | |
| 003 | SwePub | |
| 008 | 240701s2003 | |||||||||||000 ||eng| | |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:19290452 URI |
| 024 | 7 | a https://doi.org/10.2337/diabetes.52.2.2832 DOI |
| 040 | a (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Virtanen, KA4 aut |
| 245 | 1 0 | a Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects |
| 264 | 1 | b American Diabetes Association,c 2003 |
| 520 | a We evaluated the effects of rosiglitazone (4 mg b.i.d.) and metformin (1 g b.i.d.) monotherapy for 26 weeks on adipose tissue insulin-stimulated glucose uptake in patients (n = 41) with type 2 diabetes. Before and after the treatment, glucose uptake was measured using 2-[18F]fluoro-2-deoxyglucose and positron emission tomography and adipose tissue masses were quantified using magnetic resonance imaging. Rosiglitazone improved insulin-stimulated whole-body glucose uptake by 44% (P < 0.01 vs. placebo). Mean body weight was unchanged in the rosiglitazone group, while it decreased by 2.0 kg in the metformin group (P < 0.05 vs. placebo). In visceral adipose tissue, glucose uptake increased by 29% (from 17.8 ± 2.0 to 23.0 ± 2.6 μmol · kg−1 · min−1, P < 0.05 vs. placebo) in the rosiglitazone group but to a lesser extent (17%) in the metformin group (from 16.2 ± 1.5 to 18.9 ± 1.7 μmol · kg−1 · min−1, P < 0.05 vs. baseline). Because the visceral adipose tissue mass simultaneously decreased with both treatments (P < 0.05), no change was observed in total visceral glucose uptake per depot. Rosiglitazone significantly enhanced glucose uptake in the femoral subcutaneous area, either when expressed per tissue mass (from 10.8 ± 1.2 to 17.1 ± 1.7 μmol · kg−1 · min−1, P < 0.01 vs. placebo) or per whole-fat depot (P < 0.05 vs. placebo). In conclusion, metformin treatment resulted in improvement of glycemic control without enhancement of peripheral insulin sensitivity. The improved insulin sensitivity of the nonabdominal subcutaneous adipose tissue during treatment with rosiglitazone partly explains the enhanced whole-body insulin sensitivity and underlies the central role of adipose tissue for action of peroxisome proliferator-activated receptor γ agonist in vivo. | |
| 700 | 1 | a Hallsten, K4 aut |
| 700 | 1 | a Parkkola, R4 aut |
| 700 | 1 | a Janatuinen, T4 aut |
| 700 | 1 | a Lonnqvist, Fu Karolinska Institutet4 aut |
| 700 | 1 | a Viljanen, T4 aut |
| 700 | 1 | a Ronnemaa, T4 aut |
| 700 | 1 | a Knuuti, J4 aut |
| 700 | 1 | a Huupponen, R4 aut |
| 700 | 1 | a Lonnroth, P4 aut |
| 700 | 1 | a Nuutila, P4 aut |
| 710 | 2 | a Karolinska Institutet4 org |
| 773 | 0 | t Diabetesd : American Diabetes Associationg 52:2, s. 283-290q 52:2<283-290x 0012-1797x 1939-327X |
| 856 | 4 | u http://diabetes.diabetesjournals.org/content/52/2/283.full.pdf |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:1929045 |
| 856 | 4 8 | u https://doi.org/10.2337/diabetes.52.2.283 |
Hitta mer i SwePub
- Av författaren/redakt...
- Virtanen, KA
- Hallsten, K
- Parkkola, R
- Janatuinen, T
- Lonnqvist, F
- Viljanen, T
- visa fler...
- Ronnemaa, T
- Knuuti, J
- Huupponen, R
- Lonnroth, P
- Nuutila, P
- visa färre...
- Artiklar i publikationen
- Diabetes
- Av lärosätet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
